NCT07709299Not yet recruitingEarly phase 1
Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection
Safety and Feasibility of Autologous Cytokine Induced Killer (CIK) Cells Infusion as an Adjuvant Therapy in Post Resection Hepatocellular Carcinoma (HCC) Patients
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had surgery to remove their liver tumor. The patient's own blood cells are collected and grown in a laboratory to create the CIK cells, which are then given back to the patient through six intravenous infusions over about two months. Patients are followed for six months to check for side effects and early signs of whether the cancer returns.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- First submitted
- 30 Jun 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- Royan Institute
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07709299
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 6
- From 1 Jul 2026 to the primary completion date, 31 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any cell therapy or immunotherapy in the past 6 months, or current participation in another clinical study
- Another malignancy (prior or concurrent) differing from HCC in primary site or histology
Other illness
- Active infection or uncontrolled viremia (particularly HBV, HCV, or HIV)
- Clinically significant cardiovascular disease (e.g., heart failure, serious arrhythmia, symptomatic coronary artery disease)
- History of organ transplantation
- Primary or secondary immunodeficiency, or active autoimmune disease
- Severe allergic disorder or history of anaphylaxis
Other
- Pregnancy or breastfeeding at study entry
- Women of childbearing potential intending to become pregnant
Who the study is looking for
- Age between 18 and 80 years
- Documented HCC at BCLC stage 0-A, having undergone surgical tumor resection
- Single tumor or ≤3 nodules, each ≤3 cm
- Child-Pugh score A-B
- ECOG performance status 0-1
- Confirmed cancer-free status one month after surgery
- Written informed consent
- Leukocyte count \> 3 × 10⁹/L
- Absolute neutrophil count (ANC) ≥ 1,000/µL
- Hemoglobin ≥ 8.5 g/dL
- Platelet count \> 50 × 10⁹/L
- BUN and serum creatinine ≤ 1.5 × upper limit of normal No extrahepatic abdominal disease spread, confirmed by abdominal CT/MRI
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Liver Transplant and Surgery Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.